Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $1.01
0% from low
Exchange
OTC Link
CS
Borrow rate
75.06%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $204.6K | $436.4K | $619.0K | $870.3K | $1.5M | $1.0M |
| Gross profit | −$204.6K | −$436.4K | −$619.0K | −$870.3K | −$1.5M | −$1.0M |
| Gross margin | — | — | — | — | — | — |
| R&D | $8.0M | $15.2M | $17.8M | $37.5M | $47.1M | $18.3M |
| Operating income | −$13.2M | −$20.9M | −$27.9M | −$53.3M | −$63.1M | −$29.2M |
| EBITDA | −$13.0M | −$20.4M | −$27.6M | −$49.1M | −$61.0M | −$28.2M |
| Net income | −$12.8M | −$20.3M | −$31.6M | −$51.7M | $514.2M | −$32.3M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -14.25 | -22.53 | -34.76 | -56.67 | 534.29 | -30.82 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.01 | $-1.01–$-1.01 | 1 |
| 2027 | $0 | $-0.96 | $-0.96–$-0.96 | 1 |
Forward consensus · source: Financial Modeling Prep
NEXIMMUNE INC
No one on the platform currently holds NEXI.
No tracked institution reports a position in NEXI as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-10-19 | 1-for-25reverse |
No one on the platform has traded NEXI yet.
| $221 |
| — |
| MDVLQMedAvail Holdings, Inc. | $0.00 | +0.00% | $161 | — |
| MICRDMicron Solutions, Inc. | $0.00 | +0.00% | $317 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $NEXI (NexImmune, Inc.) based on financial data and reported results. #NEXI
View on StockTwits ↗$NEXI Digging the pivot to AIM INJ platform. Preclinical work looks promising. Watching closely for IND filing and potential breakthrough in T-cell therapies. Small position for now. an honest look at company progress: https://beyondspx.com/article/neximmune-inc-nexi-pioneering-a-novel-approach-to-immunotherapy
View on StockTwits ↗$NEXI NexImmune, Inc. (NASDAQ:NEXI): A Promising Biotech Poised for Transformation https://beyondspx.com/article/navigating-the-uncertainty-a-deep-dive-into-neximmune-s-nexi-resilience-and-future-prospects
View on StockTwits ↗$NEXI Navigating the Uncertainty: A Deep Dive into NexImmune’s (NEXI) Resilience and Future Prospects https://beyondspx.com/article/navigating-the-uncertainty-a-deep-dive-into-neximmune-s-nexi-resilience-and-future-prospects
View on StockTwits ↗$NEXI Nice! $ALBT ready next. Good luck. No shares to short.
View on StockTwits ↗$LASE Shorts Should Get Out Of There While They Still Have Time ⏰ ⚠️ Stocks To Watch : $OTRK $PDYN $BPTH $NEXI
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.